Muhammad Erfan Uddin, Eric D Eisenmann, Yang Li, Kevin M Huang, Dominique A Garrison, Zahra Talebi, Alice A Gibson, Yan Jin, Mahesh Nepal, Ingrid M Bonilla, Qiang Fu, Xinxin Sun, Alec Millar, Mikhail Tarasov, Christopher E Jay, Xiaoming Cui, Heidi J Einolf, Ryan M Pelis, Sakima A Smith, Przemysław B Radwański, Douglas H Sweet, Jörg König, Martin F Fromm, Cynthia A Carnes, Shuiying Hu, Alex Sparreboom
Dofetilide is a rapid delayed rectifier potassium current inhibitor widely used to prevent the recurrence of atrial fibrillation and flutter. The clinical use of this drug is associated with increases in QTc interval, which predispose patients to ventricular cardiac arrhythmias. The mechanisms involved in the disposition of dofetilide, including its movement in and out of cardiomyocytes, remain unknown. Using a xenobiotic transporter screen, we identified MATE1 ( SLC47A1 ) as a transporter of dofetilide and found that genetic knockout or pharmacological inhibition of MATE1 in mice was associated with enhanced retention of dofetilide in cardiomyocytes and increased QTc prolongation...
August 3, 2022: International Journal of Molecular Sciences